PTIX Quote, Financials, Valuation and Earnings

BioMarin Pharmaceutical has a net margin of -- compared to Protagenic Therapeutics's net margin of 24.92%. Protagenic Therapeutics's return on equity of -- beat BioMarin Pharmaceutical's return on equity of 9.62%.

Protagenic Therapeutics has a consensus price target of --, signalling upside risk potential of 5970.46%. On the other hand BioMarin Pharmaceutical has an analysts' consensus of $95.52 which suggests that it could grow by 64.4%. Given that Protagenic Therapeutics has higher upside potential than BioMarin Pharmaceutical, analysts believe Protagenic Therapeutics is more attractive than BioMarin Pharmaceutical.

Protagenic Therapeutics has a beta of 0.354, which suggesting that the stock is 64.562% less volatile than S&P 500. In comparison BioMarin Pharmaceutical has a beta of 0.168, suggesting its less volatile than the S&P 500 by 83.229%.

Protagenic Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagenic Therapeutics pays -- of its earnings as a dividend. BioMarin Pharmaceutical pays out -- of its earnings as a dividend.

Protagenic Therapeutics quarterly revenues are --, which are smaller than BioMarin Pharmaceutical quarterly revenues of $745.1M. Protagenic Therapeutics's net income of -$1.4M is lower than BioMarin Pharmaceutical's net income of $185.7M. Notably, Protagenic Therapeutics's price-to-earnings ratio is -- while BioMarin Pharmaceutical's PE ratio is 21.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics is 0.13x versus 3.89x for BioMarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Cormedix has a net margin of -- compared to Protagenic Therapeutics's net margin of 52.82%. Protagenic Therapeutics's return on equity of -- beat Cormedix's return on equity of 23.7%.

Protagenic Therapeutics has a consensus price target of --, signalling upside risk potential of 5970.46%. On the other hand Cormedix has an analysts' consensus of $19.00 which suggests that it could grow by 69.34%. Given that Protagenic Therapeutics has higher upside potential than Cormedix, analysts believe Protagenic Therapeutics is more attractive than Cormedix.

Protagenic Therapeutics has a beta of 0.354, which suggesting that the stock is 64.562% less volatile than S&P 500. In comparison Cormedix has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.146%.

Protagenic Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagenic Therapeutics pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

Protagenic Therapeutics quarterly revenues are --, which are smaller than Cormedix quarterly revenues of $39.1M. Protagenic Therapeutics's net income of -$1.4M is lower than Cormedix's net income of $20.6M. Notably, Protagenic Therapeutics's price-to-earnings ratio is -- while Cormedix's PE ratio is 51.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics is 0.13x versus 8.39x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Protagenic Therapeutics's net margin of 26.7%. Protagenic Therapeutics's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Protagenic Therapeutics has a consensus price target of --, signalling upside risk potential of 5970.46%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 28.32%. Given that Protagenic Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Protagenic Therapeutics is more attractive than Regeneron Pharmaceuticals.

Protagenic Therapeutics has a beta of 0.354, which suggesting that the stock is 64.562% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Protagenic Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.31% to investors and pays a quarterly dividend of $0.88 per share. Protagenic Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Protagenic Therapeutics quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Protagenic Therapeutics's net income of -$1.4M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Protagenic Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics is 0.13x versus 4.60x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of -- compared to Protagenic Therapeutics's net margin of 21.46%. Protagenic Therapeutics's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

Protagenic Therapeutics has a consensus price target of --, signalling upside risk potential of 5970.46%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 78.72%. Given that Protagenic Therapeutics has higher upside potential than Rigel Pharmaceuticals, analysts believe Protagenic Therapeutics is more attractive than Rigel Pharmaceuticals.

Protagenic Therapeutics has a beta of 0.354, which suggesting that the stock is 64.562% less volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.398%.

Protagenic Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagenic Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Protagenic Therapeutics quarterly revenues are --, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Protagenic Therapeutics's net income of -$1.4M is lower than Rigel Pharmaceuticals's net income of $11.4M. Notably, Protagenic Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics is 0.13x versus 1.66x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.